Principal Financial Group Inc Alnylam Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

  • $160 Billion
  • Q2 2024

A detailed history of Principal Financial Group Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 14,189 shares of ALNY stock, worth $3.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,189
Previous 19,356 26.69%
Holding current value
$3.76 Million
Previous $2.89 Million 19.19%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024
SELL
$143.31 - $247.0 $740,482 - $1.28 Million
-5,167 Reduced 26.69%
14,189 $3.45 Million
Q1 2024

Apr 29, 2024
SELL
$146.51 - $198.2 $39,997 - $54,108
-273 Reduced 1.39%
19,356 $2.89 Million
Q4 2023

Feb 07, 2024
SELL
$151.41 - $196.57 $435,455 - $565,335
-2,876 Reduced 12.78%
19,629 $3.76 Million
Q3 2023

Nov 02, 2023
BUY
$170.77 - $211.65 $143,959 - $178,420
843 Added 3.89%
22,505 $3.99 Million
Q2 2023

Aug 07, 2023
BUY
$185.01 - $212.05 $125,436 - $143,769
678 Added 3.23%
21,662 $4.11 Million
Q1 2023

May 09, 2023
SELL
$182.66 - $235.53 $544,144 - $701,643
-2,979 Reduced 12.43%
20,984 $4.2 Million
Q4 2022

Feb 09, 2023
SELL
$185.53 - $241.31 $460,485 - $598,931
-2,482 Reduced 9.39%
23,963 $5.69 Million
Q3 2022

Nov 09, 2022
SELL
$138.54 - $232.0 $704,198 - $1.18 Million
-5,083 Reduced 16.12%
26,445 $5.29 Million
Q2 2022

Aug 10, 2022
BUY
$120.42 - $169.29 $368,846 - $518,535
3,063 Added 10.76%
31,528 $4.6 Million
Q1 2022

May 09, 2022
SELL
$127.18 - $173.91 $198,019 - $270,777
-1,557 Reduced 5.19%
28,465 $4.65 Million
Q4 2021

Feb 09, 2022
SELL
$159.56 - $209.29 $1.38 Million - $1.8 Million
-8,618 Reduced 22.3%
30,022 $5.09 Million
Q3 2021

Nov 09, 2021
SELL
$169.75 - $207.73 $729,076 - $892,200
-4,295 Reduced 10.0%
38,640 $7.3 Million
Q2 2021

Aug 10, 2021
BUY
$128.63 - $176.89 $367,238 - $505,020
2,855 Added 7.12%
42,935 $7.28 Million
Q1 2021

May 10, 2021
BUY
$126.83 - $175.69 $255,435 - $353,839
2,014 Added 5.29%
40,080 $5.66 Million
Q4 2020

Feb 08, 2021
BUY
$122.97 - $147.0 $602,675 - $720,447
4,901 Added 14.78%
38,066 $4.95 Million
Q3 2020

Nov 06, 2020
SELL
$121.19 - $165.49 $366,720 - $500,772
-3,026 Reduced 8.36%
33,165 $4.83 Million
Q2 2020

Aug 05, 2020
BUY
$104.21 - $156.44 $758,023 - $1.14 Million
7,274 Added 25.15%
36,191 $5.36 Million
Q1 2020

May 12, 2020
BUY
$93.12 - $133.99 $137,631 - $198,037
1,478 Added 5.39%
28,917 $3.15 Million
Q4 2019

Feb 05, 2020
SELL
$74.51 - $124.23 $6,929 - $11,553
-93 Reduced 0.34%
27,439 $3.16 Million
Q3 2019

Nov 13, 2019
SELL
$70.9 - $87.82 $73,381 - $90,893
-1,035 Reduced 3.62%
27,532 $2.21 Million
Q2 2019

Aug 12, 2019
BUY
$65.86 - $92.79 $193,233 - $272,245
2,934 Added 11.45%
28,567 $2.07 Million
Q1 2019

May 10, 2019
BUY
$72.76 - $93.45 $130,094 - $167,088
1,788 Added 7.5%
25,633 $2.4 Million
Q4 2018

Feb 14, 2019
SELL
$62.67 - $88.33 $83,789 - $118,097
-1,337 Reduced 5.31%
23,845 $1.74 Million
Q3 2018

Nov 14, 2018
BUY
$87.52 - $122.67 $78,155 - $109,544
893 Added 3.68%
25,182 $2.2 Million
Q2 2018

Aug 13, 2018
SELL
$88.31 - $107.8 $20,841 - $25,440
-236 Reduced 0.96%
24,289 $0
Q1 2018

May 14, 2018
BUY
$115.92 - $148.54 $146,406 - $187,606
1,263 Added 5.43%
24,525 $2.92 Million
Q4 2017

Feb 13, 2018
BUY
$114.49 - $139.98 $1.15 Million - $1.41 Million
10,063 Added 76.24%
23,262 $2.96 Million
Q3 2017

Nov 02, 2017
BUY
$72.53 - $118.27 $957,323 - $1.56 Million
13,199
13,199 $1.55 Million

Others Institutions Holding ALNY

# of Institutions
614
Shares Held
108M
Call Options Held
2.33M
Put Options Held
2.17M
View Full List

About ALNYLAM PHARMACEUTICALS, INC.

ALNY Quotes by TradingView
  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $32.6B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email